CANCER THERAPY BY COMBINATION USE OF ONCOLYTIC VACCINIA VIRUS AND IMMUNE CHECKPOINT INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND COMBINATION MEDICINE FOR USE IN THE CANCER THERAPY

ABSTRACT OF THE DISCLOSURE

The present invention provides a combination therapy of genetically modified vaccinia virus (particularly oncolytic vaccinia virus) and another cancer therapy for use in treating cancer, and a pharmaceutical composition and a combination kit for use in the therapy. More specifically, the invention provides a therapy with vaccinia virus containing a polynucleotide encoding interleukin-7 (IL-7) and a polynucleotide encoding interleukin-12 (IL-12) in combination with an immune checkpoint inhibitor, and a pharmaceutical composition and a combination kit for use in the therapy.

[FIG .1]